New preliminary research presented today at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions in Boston has identified a potential biological pathway linking a common gum disease bacterium to a serious condition that hardens the heart's aortic valve, and found that blocking a key inflammatory protein significantly reduced valve damage in mice.
Gum disease bacteria may spur calcium buildup in the heart's aortic valve, leading to a common and serious heart valve disease, according to the preliminary, independent research. The study was conducted using mouse and human cardiac tissue, and the findings were presented at the AHA's Basic Cardiovascular Sciences Scientific Sessions 2026 in Boston, July 13–16.
The condition the researchers investigated — calcific aortic valve stenosis, or CAVS — occurs when the aortic valve thickens and calcifies, restricting blood flow from the heart to the rest of the body. In its early stages, CAVS produces no symptoms. As it progresses, it can cause fatigue, chest pain, shortness of breath, fainting, heart failure, and death. The only established treatment for severe CAVS is valve replacement surgery — either traditional open-heart surgery or transcatheter aortic valve replacement.
Currently, there are no medications proven to prevent or slow the progression of CAVS. That absence of preventive options makes the identification of modifiable risk factors — including oral bacteria — clinically significant.
Why This Matters
Gum disease, known clinically as periodontitis, is one of the most common chronic infections in adults. According to the CDC, more than 47 percent of American adults over 30 have some form of periodontal disease, and the rate rises to over 70 percent for adults over 65.
CAVS affects an estimated 2.5 million Americans and is the most common valvular heart disease in the United States, predominantly affecting older adults. The connection between oral health and cardiovascular health has been a subject of research interest for decades, but direct biological mechanisms linking specific oral bacteria to specific cardiac diseases have been difficult to establish.
This study identifies a potential biological pathway linking chronic oral gum disease and infection to calcific aortic valve stenosis. The mechanism identified — inflammatory activation via the protein IL-1β — is notable because IL-1β is already a recognized target in cardiovascular medicine, and drugs that inhibit it exist. Whether those drugs could play a role in CAVS prevention is a question that future research may now be positioned to answer.
What We Know So Far
The research team focused on Porphyromonas gingivalis, or P. gingivalis — the bacterium that plays a disproportionately large role in causing gum inflammation and the destruction of gum tissue. P. gingivalis has previously been associated with systemic inflammation and cardiovascular risk, including plaque buildup in the arteries and coronary artery disease.
For this study, researchers measured bacterial levels in human cardiac valve tissue removed during valve replacement surgery. They compared calcified aortic valves from people with CAVS to valve tissue from patients with other non-CAVS heart valve conditions.
Chenyang Li, M.D., co-lead author, said the research team was surprised by how much P. gingivalis was present in the calcified aortic valves. Although it was not one of the most abundant bacteria overall in the valve tissue, it showed one of the largest differences in concentration between valves with CAVS and valves without CAVS.
In the mouse experiments, the researchers found that when P. gingivalis was introduced, it activated IL-1β — an inflammatory signaling protein that accelerated calcium buildup in the valve. Critically, when the researchers genetically deleted the gene for IL-1β in mice, calcification was significantly reduced even in the presence of the bacteria — pointing to IL-1β as a potentially targetable molecular link in this pathway.
The research team has already launched a follow-up clinical study in people to investigate the possible connection between periodontal disease and CAVS in human patients, according to ScienceDaily's coverage of the AHA presentation.
Where the Research Comes From
The study was conducted by researchers affiliated with the State Key Laboratory of Cardiovascular Disease at Fuwai Hospital's National Center for Cardiovascular Diseases, the Chinese Academy of Medical Sciences, and Peking Union Medical College in Beijing. It was presented as a scientific meeting abstract at a conference recognized as one of the largest global gatherings focused on fundamental and translational cardiovascular research.
The American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2026 takes place in Boston July 13–16, 2026. The AHA's own research team at the American Heart Association noted that the AHA's Healthy Smiles, Healthy Hearts initiative already supports dental professionals with educational resources about the connection between oral and cardiovascular health.
What Doctors and Experts Say
Chenyang Li, M.D., co-lead author and Ph.D. candidate at Fuwai Hospital's National Center for Cardiovascular Diseases, said in the AHA press release: "There are currently no medications proven to prevent or slow the progression of CAVS. We hope our findings demonstrating the link between periodontal disease and CAVS will stimulate further research into new preventive and therapeutic approaches for this condition."
The AHA press release emphasized that the results are preliminary and have not yet been confirmed in people. The work was presented as a scientific meeting abstract, meaning it has not yet undergone peer review or been published as a full journal paper. The researchers acknowledge this limitation directly.
What the Evidence Shows and What It Does Not
This is an important boundary to maintain clearly. The research is preliminary and pre-clinical in significant respects. Understanding what it does and does not prove is essential.
MedicalDaily Evidence Check
- Study type: Laboratory study using mouse and human cardiac valve tissue; presented as a conference abstract (not yet peer-reviewed or published as a full paper)
- Institution: Fuwai Hospital National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
- Presented at: AHA Basic Cardiovascular Sciences Scientific Sessions 2026, Boston, July 13, 2026
- What it found: P. gingivalis was present at significantly higher levels in calcified aortic valves compared to non-CAVS valves; P. gingivalis activated IL-1β inflammatory signaling in mice, accelerating valve calcification; genetic deletion of IL-1β significantly reduced calcification even in mice with the bacteria present
- What it did not prove: That gum disease causes CAVS in humans; that treating gum disease will prevent or slow CAVS; that existing IL-1β-blocking medications are effective against CAVS
- Sample consideration: Human tissue comparison used valve samples from surgical patients — a highly selected population — not a representative general population sample
- What readers should know: These findings are scientifically meaningful and motivate further research. They do not yet change clinical recommendations for CAVS screening, prevention, or treatment. Maintain good oral health regardless — there are multiple independent reasons to do so.
Who Should Pay Attention to This Research
This research is most immediately relevant to:
- Adults with diagnosed periodontal disease who also have cardiovascular risk factors
- Patients who have been told they have a mildly thickened or calcifying aortic valve on echocardiogram and are being monitored
- Older adults, in whom both periodontal disease and CAVS are most prevalent
- Cardiologists and dentists who collaborate on patient care for high-risk individuals
- Researchers studying the oral-cardiovascular axis
This research does not change what patients should do right now, but it reinforces why preventing and treating gum disease matters beyond just the mouth.
Symptoms and Warning Signs to Watch For
For gum disease: Symptoms of periodontitis include bleeding gums when brushing or flossing, persistent bad breath, red or swollen gums, gum recession making teeth appear longer, loose teeth, and pain when chewing. Gum disease in its early stages (gingivitis) is reversible with improved oral hygiene; advanced periodontitis requires professional dental treatment.
For calcific aortic valve stenosis: Early CAVS typically produces no symptoms. By the time symptoms develop, the disease is usually advanced. Symptoms include: chest tightness or pressure with exertion, shortness of breath during activity, fatigue or lightheadedness, heart palpitations, fainting or near-fainting episodes. Any new cardiac symptom, particularly in adults over 60, warrants evaluation by a physician, including a cardiac auscultation for the characteristic murmur of CAVS.
What You Can Do Now
- Maintain good oral hygiene — brush twice daily with fluoride toothpaste, floss daily, and see your dentist regularly. This advice is supported by extensive existing evidence regardless of the current finding.
- If you have been diagnosed with periodontal disease, ensure it is being actively treated. Scaling and root planing, and in some cases surgical treatment, can substantially reduce P. gingivalis burden.
- If you are at risk for CAVS — particularly if you are over 60, have a history of cardiovascular disease, or have a bicuspid aortic valve — ask your cardiologist whether routine echocardiographic monitoring is appropriate for your situation.
- Do not begin or discontinue any medication based on this preliminary research. The identification of IL-1β as a potential molecular link is scientifically interesting but does not yet support clinical intervention with existing IL-1β inhibitors for CAVS prevention.
- Share this research with your dentist and cardiologist at your next visit — particularly if you have both risk factors.
Cost and Access: What Patients Should Know
Regular dental care — the most practical implication of this research — is covered by most private dental insurance plans and by Medicaid dental benefits in most states. Adults without dental insurance can access care through community health centers and dental school clinics, which typically offer substantially reduced costs.
For patients at risk for CAVS, echocardiography — the standard test for detecting valve abnormalities — is covered by most insurance plans when ordered for cardiac symptoms or monitoring of known valve disease. Echocardiography is available at most hospital cardiology departments, outpatient cardiology practices, and some primary care facilities.
What Happens Next
The research team has already launched a clinical study in people to further investigate the periodontitis-CAVS connection, as noted in the ScienceDaily report on the AHA presentation. That clinical study is expected to use human subjects to test whether P. gingivalis burden correlates with CAVS severity, and whether treating periodontal disease affects the progression of valve calcification.
The AHA Basic Cardiovascular Sciences Scientific Sessions continue in Boston through July 16. Additional research on this topic is expected to be submitted to peer-reviewed journals for full publication in the coming months. MedicalDaily will report when the full peer-reviewed paper is published.
The Bottom Line
A preliminary study presented today at the American Heart Association found that a common gum disease bacterium — P. gingivalis — was significantly more abundant in calcified heart valves than in healthy ones, and that an inflammatory protein activated by the bacteria appeared to drive valve calcification in mice. Blocking that protein significantly reduced the damage. The research does not yet prove that gum disease causes heart valve disease in people, and it does not yet change clinical treatment guidelines. But it adds meaningful evidence to the case for treating periodontal disease as more than a dental problem — and it opens a new line of investigation in a condition for which there are currently no proven preventive medications.
